India regulates plant-based medicines through three legally separate doors, and only one of them is treated like a modern drug. That door is the phytopharmaceutical category — a purified, standardised plant fraction that must be characterised by at least four bioactive markers before CDSCO will look at it as a therapeutic. A review published in Discover Pharmaceutical Sciences and reported by Scienmag and Bioengineer on 10 November 2026 has put the full rulebook back in view: the statutory definition, the pharmacopoeial monographs, the analytical workload, and the attrition data that shows how few botanical candidates actually make it.
🌿 The 2015 Notification That Created a New Drug Class
The category did not emerge from case law or state licensing practice. It was created by gazette notification G.S.R. 918(E) on 30 November 2015, which inserted the phytopharmaceutical definition into the Drugs and Cosmetics Rules, 1945. The rule describes a phytopharmaceutical as a purified and standardised fraction containing a minimum of four bioactive phytochemical markers, derived from an extract of a medicinal plant or its part, intended for therapeutic use.
Two structural features matter for anyone buying or importing these products. First, under Rule 2(eb) and Rule 122E, a phytopharmaceutical is evaluated as a new drug where there is no extensive prior usage or established regulatory clearance — which places it on the same evidence treadmill as a synthetic molecule. Second, the route restrictions are explicit: oral and topical administration are permitted, intravenous dosing is excluded from the category.
This is why the category is often misunderstood. A classical Ayurveda, Siddha or Unani formulation, or an Ayurvedic proprietary medicine, sits under the Ministry of AYUSH and is validated largely against classical literature. A phytopharmaceutical sits under CDSCO with multi-marker characterisation requirements that are engineered to match synthetic-drug standards. Same plant, different regulatory universe.
🔬 What “Four Markers” Actually Demands of a Manufacturer
The four-marker rule sounds like a labelling formality. In practice it drives the entire chemistry, manufacturing and controls package, because a marker must be quantified, reproducibly, batch after batch. The Indian Pharmacopoeia Commission moved this from guidance to compendial standard by introducing dedicated Phytopharmaceutical Ingredient (PPI) monographs in IP 2022, each requiring a minimum of four quantified biological or chemical markers.
The worked example in the Indian Pharmacopoeia is Andrographis paniculata PPI, which specifies four named compounds: andrographolide, andrograpanin, neo-andrographolide, and 14-deoxy-11,12-didehydroandrographolide. A supplier claiming an Andrographis phytopharmaceutical must be able to quantify all four, not just the headline marker.
- Authentication first — macroscopic morphology, then microscopic histology (stomatal number per mm² of epidermis, stomatal index, vein-islet density, vein-termination count, palisade ratio), then preliminary phytochemical colour-reaction screening.
- Physical standardisation — foreign organic matter, moisture and volatile matter by loss on drying or azeotropic distillation, total ash and acid-insoluble ash as adulteration markers, plus refractive index, optical rotation, viscosity and melting point.
- Quantification — HPLC for marker assay, HPTLC for fingerprinting and process optimisation, GC-MS and LC-MS/MS for structure confirmation and contaminant screening.
- Contaminant screens — pesticide residues by GC-MS to WHO/FAO limits, heavy metals, radioactive contamination, total microbial load, E. coli and moulds, and aflatoxins, which the standards require to be eliminated.
- Extraction control — ultrasound-assisted, microwave-assisted, supercritical CO₂ and enzyme-assisted extraction, followed by fractionation via molecular distillation, simulated moving bed or counter-current chromatography.
⚠️ Buyer’s read: a certificate of analysis that reports a single marker (say, “andrographolide 10%”) is not evidence of a phytopharmaceutical. For this category the COA should show four or more quantified markers plus the contaminant panel. If it doesn’t, ask for the full specification before treating the product as CDSCO-regulated.
📉 The Attrition Problem: 7.65% Reach Approval
The review’s most sobering contribution is the conversion data. Across 1,517 botanical clinical trials captured in trial registries, only 116 — 7.65 percent — reached Phase 4 market approval. On the longer historical record, 26 of 91 plant-derived candidates (28.57 percent) gained authorisation.
The regulatory gate that explains much of that washout sits in Appendix IB of Schedule Y. Phytopharmaceutical candidates must file comprehensive preclinical data, including 28 to 90 days of repeated-dose oral toxicity in two animal species, genotoxicity and teratogenicity studies. Stability must be demonstrated at room temperature and under accelerated conditions of 40°C at 75 percent relative humidity across 0, 1, 2, 3 and 6 months. These are the same bars applied to synthetic new drugs.
The most advanced Indian program cited is Sun Pharma’s AQCH, an aqueous extract of Cocculus hirsutus developed with the Department of Biotechnology, ICGEB and CSIR-IIIM for dengue and investigated for COVID-19. It has completed Phase 1 safety trials and reached Phase 3 clinical investigation — the clearest proof that a multi-marker standardised botanical can clear the same clinical gates as a conventional drug.
Institutional scaffolding has followed the rules rather than preceded them: CSIR established a Phytopharmaceutical Mission to drive discovery and formulation research, while the Indian Pharmacopoeia Commission built the PPI monograph series that gives regulators and buyers a shared analytical reference.
🌍 Why India’s Pathway Looks Different From Everyone Else’s
Regulators elsewhere have not converged on a multi-marker botanical drug class, and the divergence shapes what an importer can legally expect:
- United States — herbal products are predominantly classified as dietary supplements, with no pre-market FDA review of safety and efficacy unless post-market concerns emerge. Complex botanical drug products can take the Investigational New Drug route instead.
- European Union — traditional herbal medicines may be marketed without clinical trials where documented medicinal use spans at least 30 years, including 15 within the EU; stand-alone or mixed applications require sponsor-generated clinical data.
- Canada — natural health products are regulated under dedicated rules mandating pre-approval and GMP compliance.
- Middle East and Russia — herbal products are treated strictly as conventional pharmaceuticals with full chemistry, manufacturing and controls requirements.
- China — Traditional Chinese Medicine is modernised under the Drug Administration Law and Healthy China 2030.
⚠️ Compliance reminder: the same bottle can be a supplement in one market and an unapproved new drug in another. Exporting an Indian phytopharmaceutical to the US does not inherit its CDSCO status, and importing a US botanical supplement into India does not make it a phytopharmaceutical. Classification is destination-specific and must be settled before shipment — the same principle that applies to IMSDA’s verified member directory listing of distributors who handle regulated product categories.
✅ Practical Checklist Before Sourcing a Phytopharmaceutical
- Confirm the regulatory identity in writing. Ask whether the product is a phytopharmaceutical under Rule 2(eb), an Ayurvedic proprietary medicine, or a classical AYUSH formulation. The evidence package differs completely.
- Demand four quantified markers. A named spec should mirror the PPI monograph structure — multiple markers, defined assay limits, defined analytical method.
- Check the route. Oral and topical only. A phytopharmaceutical presented for intravenous use sits outside the category.
- Verify the stability dataset. Request the 40°C/75% RH accelerated data at 0, 1, 2, 3 and 6 months, not just a single time-point result.
- Review the contaminant panel. Pesticide residues to WHO/FAO limits, heavy metals, microbial load and a confirmed aflatoxin result.
- Map the batch to the source plant. Geographic origin, harvest stage and post-harvest handling drive batch-to-batch variability; a supplier who cannot name the collection region cannot control the markers.
- Match the claim to the market. Settle supplement-versus-drug classification in the destination jurisdiction before pricing the shipment.
🔎 What This Means for Buyers and Importers
India has done something most regulators have avoided: it created a legal route for plant-derived medicine that does not dilute the evidence standard. The four-marker requirement is the mechanism — it converts “herbal” from a marketing descriptor into an analytical specification. For buyers, that is an advantage. A product that genuinely carries a phytopharmaceutical dossier is documented far more heavily than a supplement, and the Indian Pharmacopoeia monographs give an independent way to check the supplier’s claims rather than accept them.
The reverse is also true. Products marketed with botanical language but without a phytopharmaceutical dossier should not be assumed to carry that evidence. With 7.65 percent of botanical trials reaching approval, the gap between an extract and an approved phytopharmaceutical is the entire clinical program — and no certificate of analysis closes it.
Sources: Jadhav R. et al., “Regulations, current development, and future prospects of phytopharmaceuticals, a new class of herbal medicines in India”, Discover Pharmaceutical Sciences (2025) — a systematic review screening 85 peer-reviewed papers, monographs and patents from 2004–2025; reported by Scienmag and Bioengineer.org, 10 November 2026. Statutory references: Gazette Notification G.S.R. 918(E) dated 30 November 2015; Rules 2(eb) and 122E, Drugs and Cosmetics Rules, 1945; Appendix IB of Schedule Y; Indian Pharmacopoeia 2022 Phytopharmaceutical Ingredient monographs.
For more information, contact IMSDA at contact@indiamedicine.org.